New from NCI |
Exercise as Cancer Treatment |
| | Most people who have had cancer tend to be inactive both during and after treatment, even though research shows they would benefit from more activity. Learn about updated guidelines on exercise and what these new guidelines mean for patients, survivors, and doctors. |
Targeted Drug Trio for Colon and Rectal Cancer |
| | Results from a new clinical trial show that some patients with an aggressive form of colorectal cancer that has spread to other parts of the body benefit from treatment with three targeted cancer drugs. Learn more about this treatment. |
Video—Clinical Trial for Gastrointestinal Tumors That Can Be Removed with Surgery
Learn about a phase 2 clinical trial taking place at the NIH Clinical Center in Bethesda, Maryland for people with tumors in the stomach or intestines that can be removed with surgery. |
Understanding Cervical Changes: Next Steps after an Abnormal Screening Test |
| | This page includes the latest recommendations from the Centers for Disease Control and Prevention for who should get the HPV vaccine, as well as information about screening for cervical cancer. Learn more about treatment and follow-up for abnormal Pap test, HPV test, and Pap/HPV cotest results that aren’t cancer. |
Opportunities in Cancer Research: Artificial Intelligence
Artificial intelligence refers to a computer performing tasks that commonly require human intelligence. Its use in research and health care has exploded and its potential is vast. Learn more in this chapter of the NCI Annual Plan & Budget Proposal for Fiscal Year 2021.
|
PDQ Cancer Information Summary Updates |
Mycosis Fungoides and Sézary Syndrome Treatment
We’ve revised our treatment summary on mycosis fungoides and Sézary syndrome with updated information on treatment options and the treatments used for different stages of disease. |
Drug Information Updates |
Niraparib Use in Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
We’ve updated our drug information summary with an expanded Food and Drug Administration approval. Niraparib tosylate monohydrate (Zejula) is now approved for use in certain adults with advanced disease who have already received at least three chemotherapy regimens. |
No comments:
Post a Comment